ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Given Average Rating of "Buy" by Analysts

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) has received a consensus rating of "Buy" from the nine ratings firms that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation, seven have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $80.13.

Several brokerages recently commented on ANIP. HC Wainwright reiterated a "buy" rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a report on Monday, March 17th. JPMorgan Chase & Co. initiated coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, March 12th. They set an "overweight" rating and a $85.00 price objective on the stock. Guggenheim reissued a "buy" rating and set a $86.00 target price on shares of ANI Pharmaceuticals in a research report on Monday, May 12th. Truist Financial upped their target price on shares of ANI Pharmaceuticals from $62.00 to $65.00 and gave the company a "hold" rating in a research note on Monday, April 21st. Finally, Wall Street Zen cut shares of ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Thursday, April 24th.

Insiders Place Their Bets

In other news, insider Christopher Mutz sold 4,000 shares of ANI Pharmaceuticals stock in a transaction that occurred on Wednesday, May 14th. The shares were sold at an average price of $60.45, for a total value of $241,800.00. Following the transaction, the insider now owns 107,317 shares of the company's stock, valued at $6,487,312.65. The trade was a 3.59% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, SVP Ori Gutwerg sold 881 shares of the firm's stock in a transaction that occurred on Thursday, May 15th. The stock was sold at an average price of $60.07, for a total transaction of $52,921.67. Following the sale, the senior vice president now owns 89,897 shares of the company's stock, valued at $5,400,112.79. The trade was a 0.97% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 5,681 shares of company stock worth $346,854. 11.10% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On ANI Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Hohimer Wealth Management LLC boosted its position in shares of ANI Pharmaceuticals by 5.2% in the 1st quarter. Hohimer Wealth Management LLC now owns 4,989 shares of the specialty pharmaceutical company's stock valued at $334,000 after purchasing an additional 247 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of ANI Pharmaceuticals by 3.6% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,523 shares of the specialty pharmaceutical company's stock valued at $582,000 after acquiring an additional 364 shares during the period. Natixis Advisors LLC lifted its position in shares of ANI Pharmaceuticals by 2.3% in the 4th quarter. Natixis Advisors LLC now owns 18,601 shares of the specialty pharmaceutical company's stock valued at $1,028,000 after acquiring an additional 417 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in ANI Pharmaceuticals by 0.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 48,322 shares of the specialty pharmaceutical company's stock worth $3,235,000 after purchasing an additional 423 shares during the period. Finally, Advisors Asset Management Inc. purchased a new position in ANI Pharmaceuticals during the 1st quarter worth approximately $28,000. 76.05% of the stock is owned by institutional investors and hedge funds.

ANI Pharmaceuticals Price Performance

ANIP opened at $64.66 on Friday. ANI Pharmaceuticals has a 52-week low of $52.50 and a 52-week high of $77.00. The company has a 50 day moving average of $64.67 and a two-hundred day moving average of $61.24. The company has a market cap of $1.40 billion, a P/E ratio of -50.91 and a beta of 0.55. The company has a quick ratio of 1.98, a current ratio of 2.66 and a debt-to-equity ratio of 1.46.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last announced its quarterly earnings results on Friday, May 9th. The specialty pharmaceutical company reported $1.70 earnings per share for the quarter, topping analysts' consensus estimates of $1.37 by $0.33. ANI Pharmaceuticals had a negative net margin of 3.12% and a positive return on equity of 21.35%. The firm had revenue of $197.12 million during the quarter, compared to analysts' expectations of $179.75 million. During the same period in the prior year, the company earned $0.82 EPS. The firm's revenue was up 43.4% on a year-over-year basis. On average, analysts expect that ANI Pharmaceuticals will post 3.86 earnings per share for the current year.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.